Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology - TC Read more about Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology - TC
Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy... - TC Read more about Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy... - TC
Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer - TC Read more about Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer - TC
Zai Lab Announces Upcoming Presentations in November Investor Conferences - TC Read more about Zai Lab Announces Upcoming Presentations in November Investor Conferences - TC
Zai Lab Announces Full Exercise of the Over-allotment Option - TC Read more about Zai Lab Announces Full Exercise of the Over-allotment Option - TC
Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer -TC Read more about Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer -TC
Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC - TC Read more about Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC - TC
Zai Lab Announces Closing of Hong Kong Secondary Listing - TC Read more about Zai Lab Announces Closing of Hong Kong Secondary Listing - TC
Zai Lab Announces Pricing of Hong Kong Secondary Listing - TC Read more about Zai Lab Announces Pricing of Hong Kong Secondary Listing - TC
Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with... - TC Read more about Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with... - TC